# Strategic Recommendation

_One page. No hedging._

---

## 1. Viable product or personal workflow tool that should stay personal?

Viable product — but only with 60–90 more days of deliberate evidence-building. The infrastructure is production-quality. The methodology (ICE, 8-gate, ITE, FP autopsy) is sound. The gap is evidence: zero confirmed contest outcomes in the ground truth corpus, an empty FP autopsy database despite 297 rejections, and a setup process that takes 2+ hours. Fix those three things and this is sellable to competitive auditors. Without fixing them, it is a sophisticated personal tool that other people cannot evaluate fairly.

---

## 2. What specific finding or audit result would prove this is ready to sell?

CHAIN-001 accepted by Immunefi as High or Critical. That single confirmation, with the report ID, the program, the claimed severity, and the fact that the compound chain (slot0 manipulation + zero-slippage sandwich) was assembled by the cross_agent_connector or flash_loan agent and then confirmed by multi-pass — not found by manual reading alone — is the exact evidence needed. The submission exists (report 78016). The outcome is pending. When that result arrives, the product is ready to sell.

If CHAIN-001 is rejected: any confirmed High from the xterio or wormhole workspaces, where the finding was not obvious from slither output alone, is sufficient.

---

## 3. What is the biggest thing that could kill this as a product?

The FP autopsy loop never gets populated. If the 297 rejected findings across 10 audits remain as `verdict:unknown` with no rejection rules recorded, the system cannot distinguish itself from a noisy generic LLM agent. Competitive auditors will test the tool, see a 68% rejection rate with unclear reasoning, and conclude it is not reliably better than asking Claude directly. The learning loop is the moat. If it does not run, there is no moat. This is a workflow discipline failure, not a technical failure — the code exists and works. The risk is that the author treats the rejection data as ephemeral rather than as the most valuable asset in the system.

---

## 4. If this becomes a product: what one feature MUST work reliably before any external user touches it?

The 8-gate pre-submission filter must run and write `gate_results.jsonl` before the submission pack is generated, for every finding, every time. If a paying customer submits a finding that fails Gate 3 (admin-only attack) to a live Immunefi program and gets rejected, the tool's credibility is damaged in a market where reputation is everything. The gate already exists and works. It must be made mandatory, not optional.

---

## 5. What should be built next, if anything?

Nothing new should be built until the existing pipeline is reliable. In order:

1. FP autopsy population (existing command, new data — today)
2. Post-triage severity validation (2 hours of code)
3. Docker/Codespace setup template (4 hours, reduces onboarding from 2 hours to 20 minutes)
4. Viz instrumentation for cross_agent_connector and multi_pass_confirm (1 day, makes the reasoning graph actually show the most valuable pipeline stages)

After those four things are done and CHAIN-001 is confirmed: build the public case study. The case study is the product.

Do not build: multi-user auth, billing infrastructure, web UI, new specialist agents, non-EVM chain support, enterprise features.

---

## 6. Complete this sentence:

"Audit-Watch is the only tool that **enforces a mandatory Impact Chain Escalation requirement on every finding — forcing root cause to corrupted state to protocol consumer to proven impact before any severity is assigned — and combines this with an 8-gate structural pre-submission filter that permanently rejects admin-only, impossible-state, and already-guarded false positives before they consume a human auditor's review time**, which means competitive auditors who use it will **spend zero time triaging the structurally-invalid 68% of AI-generated candidates and instead focus their expertise on the compound, cross-system, and novel-pattern findings that produce confirmed High and Critical contest submissions**."
